VOTIS Subdermal Imaging Technologies News
7 articles
growth-positive
VOTIS SUBDERMAL IMAGING TECHNOLOGIES, LTD. ANNOUNCES ENROLLMENT OF FIRST HUMAN SUBJECT IN PILOT FEASIBILITY STUDY OF PEDCHECK™ AT HADASSAH MEDICAL CENTER IN JERUSALEM
VOTIS Subdermal Imaging Technologies has enrolled the first patient in a feasibility study for its PedCheckTM device at Hadassah Medical Center in Jerusalem. The study aims to test the feasibility, usability, and safety of the device, which is designed to non-invasively measure Peripheral Arterial Disease (PAD) in the foot. The PedCheckTM directs light into the foot and measures its scattering and absorption to provide information about the location and severity of the disease. The study addresses the need for an efficient and accurate tool for PAD assessment, particularly in patients with diabetes. VOTIS is proud to begin the clinical trial at Hadassah Hospital, a leading medical center known for its use of advanced technology.
PartnersCustomers
growth-positive
Finding diabetic foot disease before symptoms show up
Israeli startup Votis has developed a noninvasive device that can identify peripheral artery disease in its early stages. The device assesses the blood and oxygen in the feet of people with diabetes, allowing for early detection and more treatment options. Votis plans to release the device in the US, Europe, and India in 2022 after completing medical trials and obtaining regulatory clearance. The company has raised $2.5 million in funding from investors in Israel, Britain, Italy, and the US. Votis aims to provide doctors and healthcare practitioners with a screening device that can be easily used and administered.
Customers
growth-positive
VOTIS Subdermal Imaging Technologies Raises US$2.5 Million
VOTIS Subdermal Imaging Technologies, Ltd. has raised US$2.5 million in a private placement of equity to a consortium of investors. The funds will be used to complete the development of the companys suite of medical devices and prepare for registration of the devices for sale in multiple countries. VOTIS plans to release its devices commercially in the US, Europe, and India in 2022. The companys devices are designed to help people with peripheral artery disease (PAD) by assessing blood flow and oxygen levels within the foot. The early diagnosis of PAD can lead to crucial treatment and potentially eliminate the need for amputation. PAD affects over 200 million people worldwide, with a significant economic burden in the US. VOTIS aims to address the challenge of early diagnosis and provide non-invasive solutions.
Investment
growth-positive
VOTIS Subdermal Imaging Technologies And ii Ventures Announce Plans To Develop Preventative Medicine Devices To Screen For Peripheral Artery Disease In India
VOTIS Subdermal Imaging Technologies, an Israeli corporation, and ii Ventures Private Limited, an Indian company, have entered into a memorandum of understanding to develop a system to screen the largely rural Indian population for peripheral artery disease (PAD). The devices will utilize the same technology that VOTIS is building into other devices intended for use in the US and Europe. The devices are non-invasive and do not use X-rays or other ionizing radiation. They are inexpensive and dependable. VOTIS plans to release its devices commercially in 2022.
PartnersExpand
growth-positive
VOTIS Subdermal Imaging Technologies Licenses Imaging Technology From Columbia University
VOTIS Subdermal Imaging Technologies has licensed an imaging technology from Columbia University to develop medical devices for peripheral artery disease (PAD) patients. The technology, called vascular optical tomographic imaging (VOTI), can identify problems with blood flow and oxygenation deep within the tissue of the foot. VOTIS plans to release its suite of devices commercially in 2022. PAD affects more than 200 million people worldwide, and early detection and treatment are crucial to reducing amputations and disabilities. The license grants VOTIS exclusive worldwide rights to the intellectual property, including 10 issued U.S. patents. The terms of the license were not disclosed.
Customers
growth-positive
6 Israeli Companies At The Forefront Of Diabetes Care, Prevention, And Treatment
The article discusses several Israeli companies that are leading the way in the prevention, management, and treatment of diabetes. One of these companies is Oramed, a Tel Aviv-based pharmaceutical company that is developing an oral insulin capsule to replace injectable treatments. The companys capsules are currently in advanced clinical trials for both type 1 and type 2 diabetes. The article highlights Orameds recent announcement that it has successfully randomized more than 50 percent of the expected 285 patients in a clinical study. This article is growth-positive for Oramed as it showcases the companys innovative approach to diabetes treatment and its progress in clinical trials.
Customers
growth-positive
Finalists Announced for 2018 Diabetes Innovation Challenge
T1D Exchange has announced the finalists for the 2018 Diabetes Innovation Challenge, a competition to identify innovative solutions for diabetes. The challenge received 60 proposals from 17 countries, and 10 academic research teams and early stage companies have been named as finalists. The finalists will make presentations to a panel of judges, and winners will be announced at a live event on May 21, 2018. The challenge is presented by T1D Exchange with the support of sponsors including The Leona M. and Harry B. Helmsley Charitable Trust and JDRF. The winners will receive a total of $250,000 in cash and in-kind support for concept/product development.
Partners
